Qianjiang Yongan Pharmaceutical Co., Ltd. (SHE:002365)
China · Delayed Price · Currency is CNY 13.48
+0.48 (3.69%)
Sep 30, 2026, 3:04 PM CST
SHE:002365 Revenue
Qianjiang Yongan Pharmaceutical had revenue of 327.81M CNY in the quarter ending June 30, 2026, with 67.06% growth. This brings the company's revenue in the last twelve months to 979.49M, up 25.52% year-over-year. In the year 2025, Qianjiang Yongan Pharmaceutical had annual revenue of 783.17M, down -6.63%.
Revenue (ttm)
979.49M
Revenue Growth
+25.52%
P/S Ratio
3.98
Revenue / Employee
1.07M
Employees
912
Market Cap
3.90B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 783.17M | -55.65M | -6.63% |
| Dec 31, 2024 | 838.81M | -134.08M | -13.78% |
| Dec 31, 2023 | 972.89M | -489.56M | -33.48% |
| Jan 1, 2023 | 1.46B | -102.96M | -6.58% |
| Jan 1, 2022 | 1.57B | 392.56M | 33.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Neptunus Bioengineering | 23.66B |
| Jinling Pharmaceutical Company | 3.18B |
| Jinhe Biotechnology CO., LTD. | 2.94B |
| Zhejiang Starry Pharmaceutical | 2.46B |
| Tibet Weixinkang Medicine | 1.13B |
| Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD | 737.90M |
| Shanghai Xiao Fang Pharmaceutical | 537.42M |
| Zhejiang Yatai Pharmaceutical | 328.58M |